Vanda patents trichostatin A cancer treatment method
Summary
USPTO granted patent US12590162B2 to Vanda Pharmaceuticals Inc. covering a method of treating cancer using trichostatin A (TSA). Inventors include Mihael H. Polymeropoulos, Louis William Licamele, and Christian Lavedan. The patent contains 5 claims.
What changed
USPTO granted patent US12590162B2 on March 31, 2026, covering a method of treating cancer by administering an effective amount of trichostatin A (TSA). The patent was assigned to Vanda Pharmaceuticals Inc. and names three inventors. The filing date was April 25, 2023, and the European application number is 18306601.
Patent holders and licensees should review the scope of the 5 granted claims to understand the extent of intellectual property protection. Competitors developing TSA-based cancer treatments should assess freedom-to-operate implications. Legal counsel may advise on international patent protection status and potential licensing opportunities.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Cancer treatment
Grant US12590162B2 Kind: B2 Mar 31, 2026
Assignee
Vanda Pharmaceuticals Inc.
Inventors
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Abstract
The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
CPC Classifications
A61P 35/00 A61P 35/02 A61P 43/00 A61K 9/0019 A61K 9/0095 A61K 9/48
Filing Date
2023-04-25
Application No.
18306601
Claims
5
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.